DE69835103D1 - Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum - Google Patents

Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum

Info

Publication number
DE69835103D1
DE69835103D1 DE69835103T DE69835103T DE69835103D1 DE 69835103 D1 DE69835103 D1 DE 69835103D1 DE 69835103 T DE69835103 T DE 69835103T DE 69835103 T DE69835103 T DE 69835103T DE 69835103 D1 DE69835103 D1 DE 69835103D1
Authority
DE
Germany
Prior art keywords
leukotrienant
histaminic
airway
agonist
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69835103T
Other languages
English (en)
Other versions
DE69835103T2 (de
Inventor
K Jensen
R Lorber
R Danzig
T Medeiros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE69835103D1 publication Critical patent/DE69835103D1/de
Publication of DE69835103T2 publication Critical patent/DE69835103T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69835103T 1997-12-23 1998-12-21 Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum Expired - Lifetime DE69835103T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6863897P 1997-12-23 1997-12-23
US68638P 1997-12-23
US7863898P 1998-03-19 1998-03-19
US78638P 1998-03-19
PCT/US1998/026223 WO1999032125A1 (en) 1997-12-23 1998-12-21 Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine

Publications (2)

Publication Number Publication Date
DE69835103D1 true DE69835103D1 (de) 2006-08-10
DE69835103T2 DE69835103T2 (de) 2006-12-21

Family

ID=26749192

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835103T Expired - Lifetime DE69835103T2 (de) 1997-12-23 1998-12-21 Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum

Country Status (27)

Country Link
EP (1) EP1041990B1 (de)
JP (2) JP2001526232A (de)
KR (1) KR100737710B1 (de)
CN (1) CN1283115A (de)
AR (1) AR017224A1 (de)
AT (1) ATE331522T1 (de)
AU (1) AU758771B2 (de)
BR (1) BR9814417A (de)
CA (1) CA2315721C (de)
CO (1) CO4980868A1 (de)
CZ (1) CZ301349B6 (de)
DE (1) DE69835103T2 (de)
DK (1) DK1041990T3 (de)
ES (1) ES2263229T3 (de)
HK (1) HK1027502A1 (de)
HU (1) HUP0101369A3 (de)
ID (1) ID26390A (de)
IL (1) IL136461A0 (de)
MY (1) MY121744A (de)
NO (1) NO20003288L (de)
NZ (1) NZ520907A (de)
PE (1) PE20000126A1 (de)
PL (1) PL193131B1 (de)
PT (1) PT1041990E (de)
SA (1) SA99200013B1 (de)
SK (1) SK286103B6 (de)
WO (1) WO1999032125A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4394931T1 (de) 1992-09-03 1995-07-20 Sepracor Inc Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
US6303632B1 (en) 1992-09-03 2001-10-16 Sepracor Inc. Compositions for treating allergic and other disorders using norastemizole in combination with other active ingredients
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6248308B1 (en) 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
IT1303671B1 (it) 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
EP1000623A1 (de) * 1998-09-29 2000-05-17 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Gebrauch von epinastine als Antitussivum
US20020198246A1 (en) 1998-09-30 2002-12-26 Ono Pharmaceutical Co., Ltd. Agent for preventing and/or treating sinusitis
EP1118327A4 (de) * 1998-09-30 2006-08-02 Ono Pharmaceutical Co Vorbeugende und/oder therapeutische mittel zur behandlung der sinusitis.
AU3800601A (en) * 2000-02-03 2001-08-14 Schering Corporation Treating allergic and inflammatory conditions
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
JP2002087963A (ja) * 2000-09-08 2002-03-27 Nippon Boehringer Ingelheim Co Ltd 直接打錠により製造されたエピナスチン含有錠剤
US20020094345A1 (en) 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
PE20020324A1 (es) * 2000-10-06 2002-06-18 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina
JP4074427B2 (ja) 2000-12-18 2008-04-09 株式会社栃木臨床病理研究所 子宮内膜症の予防又は治療薬
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
MXPA03011705A (es) * 2001-06-20 2004-03-19 Schering Corp Antihistaminas para el tratamiento de congestion nasal y obstruccion nasal.
DE60232445D1 (de) 2001-06-28 2009-07-09 Ucb Farchim Sa Cetirizin und pseudoephedrin enthaltende tablette
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
AU2003264859A1 (en) * 2001-12-21 2003-12-19 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
AU2003237253A1 (en) * 2002-05-29 2003-12-19 Aventis Pharmaceuticals Holdings Inc. Method of treating asthma using fexofenadine
ATE386526T1 (de) * 2002-07-02 2008-03-15 Ucb Farchim Sa Diarylmethylpiperazines als prophylaktische oder therapeutische mittel gegen virale myocarditis
DE60322577D1 (de) * 2002-12-06 2008-09-11 Ucb Farchim Sa Tablette enthaltend efletirizin und pseudoephedrin
WO2004087095A2 (es) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Dispositivo osmótico que contiene zafirlukast y un antagonista h1
EP1468696A1 (de) * 2003-04-17 2004-10-20 Boehringer Ingelheim International GmbH Kombinationen aus Epinastin und Antiphlogistika als neue pharmazeutische Zusammensetzungen zur Behandlung von Hauterkrankungen
WO2005030331A1 (en) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
JP2007530481A (ja) * 2004-03-24 2007-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング エピナスチン及び１又は２以上の追加のミネラル又は１又は２以上の生薬のコンビネーションを含む皮膚疾患の治療用医薬組成物
TR200806298A2 (tr) 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Farmasötik formülasyon
KR20130050952A (ko) * 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
WO2012150707A1 (ja) * 2011-05-02 2012-11-08 国立大学法人熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
WO2013058527A2 (ko) * 2011-10-18 2013-04-25 주식회사 네비팜 류코트리엔 길항제와 에피나스틴의 복합제제
KR101278572B1 (ko) * 2011-10-18 2013-06-25 주식회사 네비팜 류코트리엔 길항제와 에피나스틴의 복합제제
RU2015134423A (ru) 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
AU2014249534B2 (en) 2013-03-13 2018-08-30 IRR, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
AU2014249531B2 (en) 2013-03-13 2018-11-29 IRR, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
US9636318B2 (en) * 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
KR102356601B1 (ko) 2014-06-10 2022-01-27 지엘팜텍주식회사 슈도에페드린을 함유하는 방출조절 펠렛 조성물
EP3193875B1 (de) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizin und montelukast in der behandlung von entzündungsvermittelten störungen
US9981039B2 (en) 2015-05-29 2018-05-29 Accolade Pharma Llc Composition, its preparation and method of use in treating skin disorders
KR20190008235A (ko) * 2016-05-17 2019-01-23 프로포넌트 바이오테크 게엠베하 피부 질환을 치료/예방하기 위한 카르복실산
CN109152754A (zh) * 2016-05-17 2019-01-04 拥护者生物技术有限公司 用于治疗/预防鼻充血的羧酸
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US4810502A (en) * 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US5276044A (en) * 1991-08-14 1994-01-04 Allergan, Inc. Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions
DE4203201A1 (de) * 1992-02-05 1993-08-12 Boehringer Ingelheim Kg Neue amidinderivate, ihre herstellung und verwendung
EP0902013B1 (de) * 1992-02-05 2001-12-12 Boehringer Ingelheim International GmbH Neue Amiderivate, ihre Herstellung und Verwendung als Arzneimittel mit LTB4-antagonistischer Wirkung
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
JPH08325265A (ja) * 1995-05-29 1996-12-10 Fujisawa Pharmaceut Co Ltd チアゾリルベンゾフラン誘導体の製造方法、および該製造方法に用いられる化合物
EP0780127A1 (de) * 1995-12-19 1997-06-25 The Procter & Gamble Company Nasenspray enthaltend einen Steroid und einen Antihistamin
CZ248798A3 (cs) * 1996-02-08 1999-01-13 Merck And Co., Inc. Farmaceutický prostředek
BR9709650A (pt) * 1996-06-04 1999-08-10 Procter & Gamble Aerosol nasal contendo um esteróide intransal e um anti-histamínico
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
AU6878098A (en) * 1997-04-30 1998-11-24 Warner-Lambert Company Topical nasal antiinflammatory compositions

Also Published As

Publication number Publication date
JP2001526232A (ja) 2001-12-18
DE69835103T2 (de) 2006-12-21
CZ20002198A3 (cs) 2000-11-15
CZ301349B6 (cs) 2010-01-27
NO20003288D0 (no) 2000-06-22
AR017224A1 (es) 2001-08-22
AU758771B2 (en) 2003-03-27
CO4980868A1 (es) 2000-11-27
ATE331522T1 (de) 2006-07-15
CA2315721C (en) 2008-08-12
SA99200013B1 (ar) 2006-10-02
EP1041990B1 (de) 2006-06-28
WO1999032125A1 (en) 1999-07-01
EP1041990A1 (de) 2000-10-11
DK1041990T3 (da) 2006-10-02
HUP0101369A2 (hu) 2002-03-28
PL341343A1 (en) 2001-04-09
PE20000126A1 (es) 2000-02-23
JP2011068679A (ja) 2011-04-07
PT1041990E (pt) 2006-10-31
AU1907199A (en) 1999-07-12
CN1283115A (zh) 2001-02-07
KR100737710B1 (ko) 2007-07-11
HUP0101369A3 (en) 2002-11-28
ES2263229T3 (es) 2006-12-01
ID26390A (id) 2000-12-21
HK1027502A1 (en) 2001-01-19
PL193131B1 (pl) 2007-01-31
KR20010033485A (ko) 2001-04-25
MY121744A (en) 2006-02-28
NZ520907A (en) 2004-05-28
IL136461A0 (en) 2001-06-14
SK286103B6 (sk) 2008-03-05
SK8972000A3 (en) 2001-02-12
NO20003288L (no) 2000-08-22
CA2315721A1 (en) 1999-07-01
BR9814417A (pt) 2000-10-10

Similar Documents

Publication Publication Date Title
DE69835103D1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE1079809T1 (de) Pharmazeutische zusammensetzung mit magensaftresistentem überzug und methode zur herstellung
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
ATE288273T1 (de) Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen
EE04852B1 (et) C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE69836640D1 (de) Vorrichtung zur behandlung von gewebe mit mehrfach-elektroden
DE69903515D1 (de) Zusammensetzung zur herstellung von temporären zahnkronen und haltebrücken
DE60238576D1 (de) Zusammensetzung zur Herstellung von Elektroden und Elektroden
EE9900036A (et) Uued ühendid ja kompositsioonid trüptaasi aktiivsusega seotud haiguste raviks
FI972433A0 (fi) Rantes-peptidi ja fragmentteja sekä tätä sisältäviä tulehduksen hoitoon soveltuvia koostumuksia
DE69812784D1 (de) Zusammensetzung zur Vorbeugung und Beseitigung von Pflanzenkrankheiten
DE69613063T2 (de) Zusammensetzungen und Verfahren zur Wirkungsverstärkung von Antibiotika mit Polyphenolen
EE9800234A (et) Ravimeetod ja farmatseutiline kompositsioon
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE60120416D1 (de) Polyaminoestern und deren verwendung zur herstellung von dentalmassen
ATE258062T1 (de) Verwendung von wachstumshormon freisetzenden stoffen und ihren antagonisten zur behandlung von tumoren
DE69832173D1 (de) Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung
DE69914951D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
DE19983980T1 (de) Entladungs-Oberflächenbehandlungs-Elektrode, Verfahren zur Herstellung derselben und Entladungs-Oberflächenbehandlungs-Verfahren
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition